Agenus Inc. , a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback